Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
granted Breakthrough Therapy Designation to KEYTRUDA®
(pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of
patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative,
and Anaplastic Lymphoma Kinase (ALK) rearrangement-negative non-small
cell lung cancer (NSCLC) whose disease has progressed on or following
platinum-based chemotherapy.
Language:
English
Contact:
Media Contacts:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestor Contacts:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Lung Cancer | Lymphoma | Merck | Non-Small Cell Lung Cancer | Pharmaceuticals